1. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
- Author
-
Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, and Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
- Subjects
Male ,Urologic Diseases ,Aging ,Time Factors ,Patient Dropouts ,Asia ,Biopsy ,Clinical Decision-Making ,Clinical Sciences ,Active surveillance ,Discontinuation ,Risk Assessment ,Databases ,Risk Factors ,Predictive Value of Tests ,Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium ,Cause of Death ,Humans ,Watchful Waiting ,Factual ,Early Detection of Cancer ,Aged ,Cancer ,Prostate cancer ,Prevention ,Australia ,Prostatic Neoplasms ,Prostate-Specific Antigen ,Middle Aged ,Urology & Nephrology ,Europe ,Good Health and Well Being ,North America ,Disease Progression ,Kallikreins ,Worldwide - Abstract
BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for
- Published
- 2019